* Note: Prices are in Million (M) USD.
Description:
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $9,762 M
Debt : $254 M
EBITDA : $-1,020 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: LIFE SCIENCES
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $3,000 M
Average Revenue: $5,455 M
Revenue Converted To Free Cash FLow(%): 55%
Avg Free Cash Flow Growth Per Year (Last 5 Years): 486.65%
Since Free Cash Flow (FCF) to Revenue percentage is greater than 25, 5 points assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $2,751 M
Revenue 4 Years Ago (2020-12-31): $482 M
Last 5 Years Average Revenue Growth: 94%
Since Revenue Growth is greater than 20, 5 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $240 M
Share Count 5 Years Ago (2020-12-31): $249 M
Company is buying back its own shares, 3 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Message: Cannot calculate payout ratio because EPS is either 0 or negative.
Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: 12%
Since Average ROE is between 10 - 20, 3 points assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $107
52-Week Low: $77
Threshold Price (15% Above 52-Week Low): $88
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $27,549 M
Since Market Cap is between 10B - 100B, 2 points assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 3% exposure of Total Portfolio.
Value-Trade has assigned 24 points to above BioNTech SE (BNTX) stock.
The fair value of BioNTech SE (BNTX) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
